TickerGuard
Buy Day today: Poor (44) Weak market breadth · no major macro event
GMAB

Genmab AS

Healthcare · Biotechnology

51.70$ -4.0% vs. previous close Closing price · As of: Nov 12, 2026

Ownership

Ownership Structure

Who owns Genmab AS (GMAB)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 95.7% of the shares are freely tradable; institutional investors hold 13.6%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 13.6%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 0.0%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 95.7%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 1.1%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 615Mio.

Largest Shareholders

Institutions

Institutions GMAB
Name Stake (%) Shares Change (%) Date
Paradigm Biocapital Advisors LP 2.14 13,133,131 +64.8 06/30/2026
Orbis Allan Gray Ltd 1.85 11,368,161 -12.0 06/30/2026
AllianceBernstein L.P. 1.41 8,644,877 -9.5 06/30/2026
Deerfield Management Co 1.12 6,865,000 +178.8 06/30/2026
Deep Track Capital, LP 0.92 5,650,000 +54.2 06/30/2026
Arrowstreet Capital Limited Partnership 0.81 4,975,324 +0.0 06/30/2026
BlackRock Inc 0.76 4,671,252 +3.0 06/30/2026
Sofinnova Ventures 0.66 4,045,215 +437.7 06/30/2026

Funds

Funds GMAB
Name Stake (%) Shares Change (%) Date
iShares Biotechnology ETF 0.70 4,311,497 -0.3 10/30/2026
AllianceBernstein US L/C Growth Eqty MF 0.64 3,945,189 +0.0 06/30/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: November 12, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?